Glenmark Pharmaceuticals’ arm inks pact with BeiGene

21 May 2024 Evaluate

Glenmark Pharmaceuticals’ subsidiary -- Glenmark Specialty S.A. (Glenmark) has entered into an exclusive marketing and distribution agreement with BeiGene, a global oncology company. Under this agreement, Glenmark will register and commercialize BeiGene’s oncology medicines, Tislelizumab and Zanubrutinib in India. The addition of Tislelizumab and Zanubrutinib to the company’s oncology portfolio underscores its dedication to the cancer patients’ community and its commitment to provide access to novel therapies across India.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. 


Glenmark Pharma Share Price

1465.30 -27.05 (-1.81%)
21-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1777.65
Dr. Reddys Lab 1194.55
Cipla 1465.65
Lupin 2043.30
Zydus Lifesciences 944.25
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.